Bodei and her team will evaluate which positron emission tomography findings are associated with good or poor treatment outcomes in patients who have a NET and define a standard approach for PRESCIENT (Pet REsponse CrItEria for Neuroendocrine Tumors) for reporting these findings.
What question will the researchers try to answer?
Because it is currently unclear how to best use positron emission tomography (PET) monitoring for tumor therapy response in patients who have a NET, the team will develop tumor response criteria (PRESCIENT: Pet REsponse CrItEria for Neuroendocrine Tumors).
Why is this important?
Without clear data on the usefulness of PET to assess the response in NETs, radiologists may interpret PET scans incorrectly, which could harm patients and delay progress in NET research. Therefore, a need exists to systematically study PET for treatment monitoring.
What will researchers do?
Bodei and her team will develop the response criteria by analyzing patients who have received peptide receptor-targeted radiotherapy with 177Lu-DOTATATE and who received a PET scan before and after treatment. The team will also test PRESCIENT in an independent patient population treated with PRRT and determine whether a response by PRESCIENT predicts no tumor growth in the following year.
How might this improve the treatment of NETs?
Dr. Bodei believes that the evidence-based PRESCIENT criteria will address an unmet need in NET management by helping clinicians make the right treatment decisions for patients, and allow the inclusion of PET in clinical trials to better assess the effectiveness of new drugs.
What is the next step?